Top

International Ophthalmology

Published in:

Open Access 01-02-2020 | Glaucoma | Original Paper

Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre

Authors: Péter Kóthy, Gábor Holló

Published in: International Ophthalmology | Issue 2/2020

Abstract

Purpose

To investigate the intraocular pressure (IOP)-lowering efficacy and tolerance of brinzolamide/brimonidine fixed combination (BBFC) under real-life conditions in a tertiary glaucoma centre.

Methods

Medical records of all ocular hypertensive and open-angle glaucoma patients (n = 52) treated with BBFC were retrospectively analysed.

Results

Thirty-nine patients had primary open-angle, 6 exfoliative, 2 pigment, 1 normal tension and 1 juvenile open-angle glaucoma and 3 ocular hypertension. The prior therapy was a prostaglandin analogue (PG) (n = 4), PG/timolol (n = 20), PG/timolol and topical carbonic anhydrase inhibitor (CAI; n = 19), timolol/CAI (n = 1), PG and CAI (n = 4), timolol/pilocarpine and PG (n = 1), timolol/brimonidine and PG (n = 1) and timolol/brimonidine, PG and CAI (n = 2). These were simplified to PG/timolol and BBFC (n = 41), PG and BBFC (n = 9), timolol and BBFC (n = 1) and timolol/pilocarpine, PG and BBFC (n = 1). The IOP on the study eyes was 21.2 ± 3.7 mmHg before and 16.9 ± 2.6, 16.0 ± 2.2, 17.6 ± 3.1 and 18.0 ± 3.1 mmHg after the introduction of BBFC at month 1, 3, 6 and 12, respectively (p < 0.0003 for all time points compared to baseline, p = 1.0 for all other comparisons). Thirty-one patients (59.6%) experienced no adverse event, 17 (32.7%) reported ocular and 6 (11.5%) systemic adverse events. BBFC therapy was terminated on 27 patients (51.9%): on 19 (36.5%) due to adverse events and on 8 (15.4%) due to insufficient IOP reduction.

Conclusion

In real-life practice, the introduction of BBCF allows significant and clinically meaningful IOP reduction and therapy simplification in glaucoma patients requiring complex medication, but in more than one third of the patients it is not tolerated due to adverse events.

European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: Publicomm, 2014, pp 129–191. ISBN 978-88-98320-05-9

Kass MA, Heuer DK, Higginbotham EJ et al (2002) The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):701–713CrossRef

Holló G, Katsanos A, Konstas AG (2015) Management of exfoliative glaucoma: challenges and solutions. Clin Ophthalmol 9:907–919. https://doi.org/10.2147/OPTH.S77570 CrossRefPubMedPubMedCentral

Topouzis F, Harris A, Wilson MR et al (2009) Increased likelihood of glaucoma at the same screening intraocular pressure in subjects with pseudoexfoliation: the Thessaloniki Eye Study. Am J Ophthalmol 148(4):606–613. https://doi.org/10.1016/j.ajo.2009.03.024 CrossRefPubMed

Holló G, Katsanos K, Boboridis KG et al (2018) Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs 78(1):39–64. https://doi.org/10.1007/s40265-017-0843-9 CrossRefPubMed

Holló G, Topouzis F, Fechtner RD (2014) Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother 15(12):1737–1747. https://doi.org/10.1517/14656566.2014.936850 CrossRefPubMed

Sharma S, Trikha S, Perera SA et al (2015) Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol 9:2201–2207. https://doi.org/10.2147/opth.s72380 CrossRefPubMedPubMedCentral

Realini T, Nguyen QH, Katz G et al (2013) Fixed-combination brinzolamide 1%/brimonidine 0.2% vs. monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye 27(7):841–847. https://doi.org/10.1038/eye.2013.83 CrossRefPubMedPubMedCentral

Nguyen QH, McMenemy MG, Realini T et al (2013) Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%. J Ocul Pharmacol Ther 29(3):290–297. https://doi.org/10.1089/jop.2012.0235 CrossRefPubMedPubMedCentral

10.

Katz G, Dubiner H, Samples J et al (2013) Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol 131(6):724–730. https://doi.org/10.1001/jamaophthalmol.2013.188 CrossRefPubMed

11.

Aung T, Laganovska G, Hernandez Paredes TJ et al (2014) Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 121(12):2348–2355. https://doi.org/10.1016/j.ophtha.2014.06.022 CrossRefPubMed

12.

Gandolfi SA, Lim J, Sanseau AC et al (2014) Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther 31(12):1213–1227. https://doi.org/10.1007/s12325-014-0168-y CrossRefPubMedPubMedCentral

13.

Whitson JT, Realini T, Nguyen QH et al (2013) Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 7:1053–1060. https://doi.org/10.2147/opth.s46881 CrossRefPubMedPubMedCentral

14.

Kozobolis V, Panos GD, Konstantinidis A et al (2017) Comparison of dorzolamide/timolol vs. brinzolamide/brimonidine fixed combination therapy in the management of primary open-angle glaucoma. Eur J Ophthalmol 27(2):160–163. https://doi.org/10.5301/ejo.5000826 CrossRefPubMed

15.

Weinreb RN, Bacharach J, Fechtner RD et al (2019) 24-hour intraocular pressure control with fixed-dose combination brinzolamide 1%/brimonidine 0.2%: a multicenter, randomized trial. Ophthalmology 126:1095–1104. https://doi.org/10.1016/j.ophtha.2018.10.040 CrossRefPubMed

16.

Feldman RM, Katz G, McMenemy M et al (2016) A randomized trial of fixed-dose combination brinzolamide 1%/brimonidine 0.2% as adjunctive therapy to travoprost 0.004. Am J Ophthalmol 165:188–197. https://doi.org/10.1016/j.ajo.2016.02.026 CrossRefPubMed

17.

Fechtner RD, Myers JS, Hubatsch DA et al (2016) Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye 30(10):1343–1350. https://doi.org/10.1038/eye.2016.126 CrossRefPubMedPubMedCentral

18.

Lo JS, Pang PM, Lo SC (2016) Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs. Clin Ophthalmol 10:583–586. https://doi.org/10.2147/OPTH.S98607 CrossRefPubMedPubMedCentral

19.

Jin SW, Lee SM (2018) The efficacy and safety of the fixed combination of brinzolamide 1% and brimonidine 0.2% in normal tension glaucoma: an 18-month retrospective study. J Ocul Pharmacol Ther 34(3):274–279. https://doi.org/10.1089/jop.2017.0075 CrossRefPubMed

20.

Moosavi R, Ansari E (2018) Brinzolamide/brimonidine fixed combination: simplifying glaucoma treatment regimens. Ophthalmol Ther 7:397–403. https://doi.org/10.1007/s40123-018-0150-x CrossRefPubMedPubMedCentral

21.

Chew SK, Skalicky SE, Goldberg I (2014) Brinzolamide plus brimonidine for the treatment of glaucoma: an update. Expert Opin Pharmacother 15(16):2461–2471. https://doi.org/10.1517/14656566.2014.966689 CrossRefPubMed

22.

Nguyen QH (2014) Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence 8:853–864. https://doi.org/10.2147/PPA.S53162 CrossRefPubMedPubMedCentral

Title: Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre
Authors: Péter Kóthy
Gábor Holló
Publication date: 01-02-2020
Publisher: Springer Netherlands
Keywords: Glaucoma
Timolol
Brimonidine
Carbonic Anhydrase Inhibitor
Brinzolamide
Published in: International Ophthalmology / Issue 2/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01194-6

At a glance: The STEP trials

Springer Medicine

Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects

Vision-related quality of life in patients with idiopathic macular hole

Subjective and objective depth of field measures in pseudophakic eyes: comparison between extended depth of focus, trifocal and bifocal intraocular lenses

Vertical rectus muscle union combined with lateral rectus plication for complete abducens nerve palsy

Intermediate filaments in the medial rectus muscles in patients with concomitant exotropia

A multimodal ophthalmic analysis in patients with systemic sclerosis using ocular response analyzer, corneal topography and specular microscopy